Inogen's new management and strategy are yielding results, with better-than-expected 2024 performance and a more stable base from which to keep growing the B2B business. Despite weak DTC sales, strong B2B growth drove better-than-expected sales in Q4, and Inogen likewise beat on margins. Guidance disappointed investors and prompted a 15% drop in the shares, as moderately better revenue guidance was offset by unexpected gross margin deleverage.
Medical Technology company Inogen Inc INGN reported a fourth-quarter adjusted EPS loss of 24 cents, compared to a loss of 83 cents a year ago, beating the consensus loss of 61 cents.
Inogen, Inc. (NASDAQ:INGN ) Q4 2024 Earnings Conference Call February 25, 2025 5:00 PM ET Company Participants Ryan Peterson – Investor Relations Kevin Smith – President and Chief Executive Officer Mike Bourque – Chief Financial Officer Conference Call Participants Operator Welcome to Inogen's Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
INGN and Yuwell collaborate to expand and enhance Inogen's innovation pipeline through R&D collaboration and accelerate the entry of Inogen's brand into the Chinese market.
DUBAI, UAE, Jan. 26, 2025 /PRNewswire/ -- On the eve of the Arab Health Exhibition, Yuwell Medical held its 2025 Global Core Partner Conference in Dubai , and announced a strategic investment and partnership with Inogen, a leading U.S. company in respiratory health, highlighting our joint commitment to advancing medical device solutions and deeper collaboration. Speaking at the Yuwell Medical 2025 Global Core Partner Conference, Alex WU, Chairman of Yuwell Medical, stated that as a leading enterprise in China's home medical device industry, Yuwell will rely on internal growth and external mergers and acquisitions to promote internationalisation.
Inogen (INGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
INGN's revenue growth in the fourth quarter is likely to have been boosted by continued robust adoption of its products.
INGN announces FDA clearance for the SIMEOX 200 Airway Clearance Device.
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.